Neurogene logo

NeurogeneNASDAQ: NGNE

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 March 2014

Next earnings report:

29 November 2024

Last dividends:

N/A

Next dividends:

N/A
$859.53 M
-3%vs. 3y high
71%vs. sector
-vs. 3y high
-vs. sector
-3%vs. 3y high
84%vs. sector
929.22
-3%vs. 3y high
98%vs. sector

Price

pre-market | 29 min ago
$66.15-$2.71(-3.94%)

Dividend

No data over the past 3 years
$925.00 K-$18.49 M

Analysts recommendations

Institutional Ownership

NGNE Latest News

Neurogene to Present Interim Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
businesswire.com21 October 2024 Sentiment: POSITIVE

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it will host a webcast to present interim efficacy data from the low-dose cohort of its ongoing Phase 1/2 clinical trial of NGN-401 gene therapy for pediatric patients with Rett syndrome on November 11, 2024 at 4:30 p.m. ET. Safety data from the low- and high-dose cohorts will als.

Neurogene Reports Second Quarter 2024 Financial Results and Highlights Recent Updates
businesswire.com09 August 2024 Sentiment: POSITIVE

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced second quarter 2024 financial results and highlighted recent corporate updates. “We are pleased that NGN-401 gene therapy for Rett syndrome received RMAT designation, in addition to the recent selection by the U.S. FDA for its START Pilot Program, two programs that provide distinct opp.

What type of business is Neurogene?

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

What sector is Neurogene in?

Neurogene is in the Healthcare sector

What industry is Neurogene in?

Neurogene is in the Biotechnology industry

What country is Neurogene from?

Neurogene is headquartered in United States

When did Neurogene go public?

Neurogene initial public offering (IPO) was on 07 March 2014

What is Neurogene website?

https://www.neurogene.com

Is Neurogene in the S&P 500?

No, Neurogene is not included in the S&P 500 index

Is Neurogene in the NASDAQ 100?

No, Neurogene is not included in the NASDAQ 100 index

Is Neurogene in the Dow Jones?

No, Neurogene is not included in the Dow Jones index

When was Neurogene the previous earnings report?

No data

When does Neurogene earnings report?

The next expected earnings date for Neurogene is 29 November 2024